Comparative

Human disease

benign prostatic hyperplasia

MONDO:0010811

Mondo defines it as: “A non-cancerous nodular enlargement of the prostate gland. It is characterized by the presence of epithelial cell nodules, and stromal nodules containing fibrous and smooth muscle elements. It is the most common urologic disorder in men, causing blockage of urine flow.”

1 disease group in OMIA reaches this disease, through OMIA's own Mondo link or its OMIM numbers. The page shows the chain. It does not say whether an animal is a model of this disease.

Animal diseases

By natural-model score for this disease, highest first. The score says how complete and how well supported each chain is, by stated rules. How the score works.

OMIA group Name Found by Species The chain reached Score
2355 Prostatic hyperplasia, benign OMIA's OMIM numbers 1 Human disease 34.0

Human genes

Each human gene of these disease groups that Open Targets links to this disease.

Open Targets links none of these groups' human genes to this disease.

Drugs tested for this disease

Each ChEMBL drug that has been tested for this disease, and the human genes above it acts on, if any. Open Targets gives some drugs, such as most enzyme replacement therapies, no target gene.

Drug Acts on Latest stage for this disease
Alfuzosin None of these genes Approved
Doxazosin None of these genes Approved
Dutasteride None of these genes Approved
Fexapotide None of these genes Approved
Finasteride None of these genes Approved
Mepartricin None of these genes Approved
Prazosin None of these genes Approved
Silodosin None of these genes Approved
Tadalafil None of these genes Approved
Tamsulosin None of these genes Approved
Terazosin None of these genes Approved
Botulinum Toxin Type A None of these genes Phase 3
Cetrorelix None of these genes Phase 3
Furosemide None of these genes Phase 3
Inulin None of these genes Phase 3
Lonidamine None of these genes Phase 3
Metformin None of these genes Phase 3
Mirabegron None of these genes Phase 3
Naftopidil None of these genes Phase 3
Saw Palmetto None of these genes Phase 3
Solifenacin None of these genes Phase 3
Tertomotide None of these genes Phase 3
Topsalysin None of these genes Phase 3
Vardenafil None of these genes Phase 3
Vibegron None of these genes Phase 3
Zanoterone None of these genes Phase 3
Fedovapagon None of these genes Phase 2/3
Letibotulinumtoxina None of these genes Phase 2/3
Onabotulinumtoxina None of these genes Phase 2/3
Adalimumab None of these genes Phase 2
Antide None of these genes Phase 2
Celecoxib None of these genes Phase 2
Chromium None of these genes Phase 2
Degarelix None of these genes Phase 2
Erteberel None of these genes Phase 2
Etonogestrel None of these genes Phase 2
Ly2452473 None of these genes Phase 2
Lycopene None of these genes Phase 2
Ozarelix None of these genes Phase 2
Paclitaxel None of these genes Phase 2
Raloxifene None of these genes Phase 2
Sildenafil None of these genes Phase 2
Taprizosin None of these genes Phase 2
Udenafil None of these genes Phase 2
Alcohol None of these genes Phase 1/2
Lemuteporfin None of these genes Phase 1/2
Aloe None of these genes Phase 1
Bupivacaine None of these genes Phase 1
Talaporfin None of these genes Phase 1
Cyproterone Acetate None of these genes Early phase 1
Papaverine None of these genes Early phase 1
Tranilast None of these genes Early phase 1
Fentanyl None of these genes Unknown
Genistein None of these genes Unknown
Levobupivacaine None of these genes Unknown
Palmidrol None of these genes Unknown
Sufentanil None of these genes Unknown
Tranexamic Acid None of these genes Unknown

The drug data is ChEMBL's, under CC BY-SA 3.0, and came through Open Targets release 26.09.